LEUKOCARE Announces Appointment of Dr Andreas Seidl as new Chief Operating Officer and member of the Executive Board

Munich, Germany (ots) - Dr Andreas Seidl, hired as new Chief
Operating Officer and member of the Executive Board, will be
responsible for managing R&D operations as well as quality and
regulatory, logistics and intellectual property of LEUKOCARE AG. He
will assume his new role on April 1, 2019.

Munich-based biotechnology company LEUKOCARE announced today the
appointment of Dr Andreas Seidl as new Chief Operating Officer and
member of the Executive Board.

Dr Andreas Seidl joins LEUKOCARE with over 17 years' experience in
analytical R&D from Sandoz/Novartis where he most recently was Head
Global Analytical Characterization & Bioanalytics. During his career
at Novartis he held different leadership positions in analytical &
pharmaceutical development, analytical characterization and quality
control of biopharmaceuticals. He coordinated the pioneering
analytical and pharmaceutical development of the first complex
biosimilar Binocrit® (INN: epoetin alfa) which gained market approval
in the European Union by EMA/EC in 2007 and was since then working on
the development of the next wave of biosimilars and innovative
biopharmaceuticals such as mAbs and fusion proteins. Dr Andreas Seidl
is a chemist by training and got his PhD from the University of
Constance/Germany.

"I am delighted to welcome Andreas Seidl to LEUKOCARE. With his
experience and proven track record in analytics and biological drug
product development he is ideally qualified to help LEUKOCARE
becoming the leading formulation developer. The entire LEUKOCARE team
and I, personally, are very much looking forward to working with
him", said Michael Scholl, CEO at LEUKOCARE.

"I am very happy to join LEUKOCARE at this exciting time in the
company's development," commented Andreas Seidl. "I look forward to
be an active part of LEUKOCARE's continued growth story towards a
leading formulation development company," stated Dr Seidl.

About LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology
platform for the protection of proteins like biopharmaceuticals to
allow the development of better products. The proprietary Stabilizing
and Protecting Solutions (SPS®) technologies are provided to
development projects of partners in the pharmaceutical and medical
device industry. LEUKOCARE's SPS® technologies improve stability and
quality of biologics like antibodies, vaccines etc. in dry and liquid
formulation including high-concentration formulations. SPS®
technologies also protect proteins in biologically functionalized
combination devices.

www.leukocare.com

Contact:
Michael Scholl
michael.scholl@leukocare.com
+49 (0) 89 7801 6650

Original-Content von: LEUKOCARE AG, übermittelt durch news aktuell